Max Crispin
Max Crispin
Professor of Glycobiology, School of Biological Sciences, University of Southampton
Verified email at - Homepage
Cited by
Cited by
Site-specific glycan analysis of the SARS-CoV-2 spike
Y Watanabe, JD Allen, D Wrapp, JS McLellan, M Crispin
Science 369 (6501), 330-333, 2020
Molecular architecture of the SARS-CoV-2 virus
H Yao, Y Song, Y Chen, N Wu, J Xu, C Sun, J Zhang, T Weng, Z Zhang, ...
Cell 183 (3), 730-738. e13, 2020
A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield
R Pejchal, KJ Doores, LM Walker, R Khayat, PS Huang, SK Wang, ...
Science 334 (6059), 1097-1103, 2011
Emerging principles for the therapeutic exploitation of glycosylation
M Dalziel, M Crispin, CN Scanlan, N Zitzmann, RA Dwek
Science 343 (6166), 1235681, 2014
Quantitative mass imaging of single biological macromolecules
G Young, N Hundt, D Cole, A Fineberg, J Andrecka, A Tyler, A Olerinyova, ...
Science 360 (6387), 423-427, 2018
Envelope glycans of immunodeficiency virions are almost entirely oligomannose antigens
KJ Doores, C Bonomelli, DJ Harvey, S Vasiljevic, RA Dwek, DR Burton, ...
Proceedings of the National Academy of Sciences 107 (31), 13800-13805, 2010
Trimeric HIV-1-Env structures define glycan shields from clades A, B, and G
GBE Stewart-Jones, C Soto, T Lemmin, GY Chuang, A Druz, R Kong, ...
Cell 165 (4), 813-826, 2016
Exploitation of glycosylation in enveloped virus pathobiology
Y Watanabe, TA Bowden, IA Wilson, M Crispin
Biochimica et Biophysica Acta (BBA)-General Subjects 1863 (10), 1480-1497, 2019
Natural variation in Fc glycosylation of HIV-specific antibodies impacts antiviral activity
ME Ackerman, M Crispin, X Yu, K Baruah, AW Boesch, DJ Harvey, ...
The Journal of clinical investigation 123 (5), 2183-2192, 2013
Vulnerabilities in coronavirus glycan shields despite extensive glycosylation
Y Watanabe, ZT Berndsen, J Raghwani, GE Seabright, JD Allen, ...
Nature communications 11 (1), 2688, 2020
Glycoprotein structural genomics: solving the glycosylation problem
VT Chang, M Crispin, AR Aricescu, DJ Harvey, JE Nettleship, JA Fennelly, ...
Structure 15 (3), 267-273, 2007
Immunogenicity of stabilized HIV-1 envelope trimers with reduced exposure of non-neutralizing epitopes
SW de Taeye, G Ozorowski, AT de la Peña, M Guttman, JP Julien, ...
Cell 163 (7), 1702-1715, 2015
SARS-CoV-2 seroprevalence and asymptomatic viral carriage in healthcare workers: a cross-sectional study
A Shields, SE Faustini, M Perez-Toledo, S Jossi, E Aldera, JD Allen, ...
Thorax 75 (12), 1089-1094, 2020
Contrasting IgG structures reveal extreme asymmetry and flexibility
EO Saphire, RL Stanfield, MDM Crispin, PWHI Parren, PM Rudd, ...
Journal of molecular biology 319 (1), 9-18, 2002
Composition and antigenic effects of individual glycan sites of a trimeric HIV-1 envelope glycoprotein
AJ Behrens, S Vasiljevic, LK Pritchard, DJ Harvey, RS Andev, SA Krumm, ...
Cell reports 14 (11), 2695-2706, 2016
The glycan shield of HIV is predominantly oligomannose independently of production system or viral clade
C Bonomelli, KJ Doores, DC Dunlop, V Thaney, RA Dwek, DR Burton, ...
PloS one 6 (8), e23521, 2011
Innate immune recognition of glycans targets HIV nanoparticle immunogens to germinal centers
T Tokatlian, BJ Read, CA Jones, DW Kulp, S Menis, JYH Chang, ...
Science 363 (6427), 649-654, 2019
Structural constraints determine the glycosylation of HIV-1 envelope trimers
LK Pritchard, S Vasiljevic, G Ozorowski, GE Seabright, A Cupo, R Ringe, ...
Cell reports 11 (10), 1604-1613, 2015
Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection
PJM Brouwer, M Brinkkemper, P Maisonnasse, N Dereuddre-Bosquet, ...
Cell 184 (5), 1188-1200. e19, 2021
Design and crystal structure of a native-like HIV-1 envelope trimer that engages multiple broadly neutralizing antibody precursors in vivo
M Medina-Ramírez, F Garces, A Escolano, P Skog, SW de Taeye, ...
Journal of Experimental Medicine 214 (9), 2573-2590, 2017
The system can't perform the operation now. Try again later.
Articles 1–20